John M.L. Ebos
Impact in
- Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- Modeling and Simulation top 0.5%
- Mathematical Biology Tumor Growth
Papers in
-
- Angiogenesis and VEGF in Cancer 18
- Oncology 23
- Cancer Cells and Metastasis 7
- Cancer Treatment and Pharmacology 6
- Cancer Immunotherapy and Biomarkers 5
- Co-authors
- Robert S. Kerbel (20 shared papers)Christina R. Lee (11 shared papers)James G. Christensen (4 shared papers)William Cruz‐Muñoz (2 shared papers)Georg A. Bjarnason (2 shared papers)Amanda Tracz (9 shared papers)Sébastien Benzekry (6 shared papers)Anthony J. Mutsaers (4 shared papers)
- Journals
- Cancer Research (6 papers)Molecular Cancer Therapeutics (3 papers)Clinical Cancer Research (3 papers)PLoS Computational Biology (3 papers)Nature Reviews Clinical Oncology (2 papers)
- Partner nations
- United StatesCanadaFrance
In The Last Decade
John M.L. Ebos
45 papers receiving 4.0k citations
John M.L. Ebos's Hit Papers
Peers
Comparison fields: 5 of 135
- Cancer Research 1.3k
- Modeling and Simulation 331
- Oncology 1.4k
- Hepatology 225
- Molecular Biology 2.1k
Countries citing papers authored by John M.L. Ebos
This map shows the geographic impact of John M.L. Ebos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M.L. Ebos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M.L. Ebos more than expected).
Fields of papers citing papers by John M.L. Ebos
This network shows the impact of papers produced by John M.L. Ebos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M.L. Ebos. The network helps show where John M.L. Ebos may publish in the future.
Co-authors
The 25 scholars most cited alongside John M.L. Ebos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis Hit paper breakdown → | 2009 | 1383 |
| 2 | Antiangiogenic therapy: impact on invasion, disease progression, and metastasis Hit paper breakdown → | 2011 | 549 |
| 3 | 2014 | 371 | |
| 4 | 2007 | 295 | |
| 5 | 2009 | 228 | |
| 6 | 2004 | 160 | |
| 7 | 2004 | 128 | |
| 8 | 2014 | 116 | |
| 9 | 2020 | 99 | |
| 10 | 2008 | 95 | |
| 11 | 2009 | 73 | |
| 12 | Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. | 2002 | 64 |
| 13 | 2015 | 48 | |
| 14 | 2020 | 47 | |
| 15 | 2015 | 47 | |
| 16 | 2005 | 35 | |
| 17 | 2005 | 34 | |
| 18 | 2014 | 34 | |
| 19 | 2009 | 33 | |
| 20 | 2013 | 30 |
About John M.L. Ebos
John M.L. Ebos is a scholar working on Molecular Biology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Biotechnology, having authored 49 papers that have together received 4.1k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (18 papers), Renal cell carcinoma treatment (9 papers), Cancer, Hypoxia, and Metabolism (8 papers), Cancer Genomics and Diagnostics (7 papers), Cancer Cells and Metastasis (7 papers), Cancer Research and Treatments (7 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). The work is most often cited by research in Cancer Research (1.3k citations), Modeling and Simulation (331 citations), Oncology (1.4k citations), Hepatology (225 citations) and Molecular Biology (2.1k citations). John M.L. Ebos has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Robert S. Kerbel, Christina R. Lee, James G. Christensen, William Cruz‐Muñoz, Georg A. Bjarnason, Amanda Tracz, Sébastien Benzekry, Anthony J. Mutsaers, Afshin Beheshti and Lynn Hlatky. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Clinical Cancer Research, PLoS Computational Biology and Nature Reviews Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.